Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks

Nucleic Acids Research

Volumn 31, Issue 15, 2003, Pages 4373-4384

  Sabourin, Michelle ^a,e   Nitiss, John L ^b   Nitiss, Karin C ^b   Tatebayashi, Kazuo ^c   Ikeda, Hideo ^d   Osheroff, Neil ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

^d University of Tokyo   (Japan)

^e PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DOUBLE STRANDED DNA; ETOPOSIDE;

ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DRUG MECHANISM; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENETIC MODEL; GENETIC RECOMBINATION; HOMOLOGOUS RECOMBINATION; LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SACCHAROMYCES CEREVISIAE; WILD TYPE; YEAST CELL; BIOLOGICAL MODEL; CELL CYCLE; CELL DIVISION; DRUG EFFECT; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM;

SACCHAROMYCES; SACCHAROMYCES CEREVISIAE;

CELL CYCLE; CELL DIVISION; DNA DAMAGE; DNA REPAIR; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; ETOPOSIDE; MODELS, GENETIC; RECOMBINATION, GENETIC; SACCHAROMYCES CEREVISIAE;

EID: 0041660961     PISSN: 03051048     EISSN: None     Source Type: Journal    
DOI: 10.1093/nar/gkg497     Document Type: Article

References (100)

1. Wang,J.C. (1996) DNA topoisomerases. Annu. Rev. Biochem., 65, 635-692.
2. Burden,D.A. and Osheroff,N. (1998) Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim. Biophys. Acta, 1400, 139-154.
3. Nitiss,J.L. (1998) Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochim. Biophys. Acta, 1400, 63-81.
4. Wang,J.C. (1998) Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine. Q. Rev. Biophys., 31, 107-144.
5. Fortune,J.M. and Osheroff,N. (2000) Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog. Nucleic Acid Res. Mol. Biol., 64, 221-253.
6. Champoux,J.J. (2001) DNA topoisomerases: structure, function and mechanism. Annu. Rev. Biochem., 70, 369-413.
7. Sabourin,M. and Osheroff,N. (2002) Topoisomerases. In Creighton,T.E. (ed.), Encyclopedia of Molecular Medicine. John Wiley & Sons, New York, NY, Vol. 5, pp. 3192-3197.
8. Wilstermann,A.M. and Osheroff,N. (2003) Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes. Curr. Top. Med. Chem., 3, 321-338.
9. Rowley,J.D. (1998) Chromosome translocations: dangerous liaisons. J. Lab. Clin. Med., 132, 244-250.
10. Baguley,B.C. and Ferguson,L.R. (1998) Mutagenic properties of topoisomerase-targeted drugs. Biochim. Biophys. Acta, 1400, 213-222.
11. Felix,C.A. (2001) Leukemias related to treatment with DNA topoisomerase II inhibitors. Med. Pediatr. Oncol., 36, 525-535.
12. Holm,C., Covey,J.M., Kerrigan,D. and Pommier,Y. (1989) Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res., 49, 6365-6368.
13. Corbett,A.H. and Osheroff,N. (1993) When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem. Res. Toxicol., 6, 585-597.
14. Howard,M.T., Neece,S.H., Matson,S.W. and Kreuzer,K.N. (1994) Disruption of a topoisomerase-DNA cleavage complex by a DNA helicase. Proc. Natl Acad. Sci. USA, 91, 12031-12035.
15. D'Arpa,P. (1994) Determinants of cellular sensitivity to topoisomerase-targeting antitumor drugs. Adv. Pharmacol., 29B, 127-143.
16. Chen,A.Y. and Liu,L.F. (1994) DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol., 34, 191-218.
17. Nitiss,J. and Wang,J.C. (1988) DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc. Natl Acad. Sci. USA, 85, 7501-7505.
18. Andersson,H.C. and Kihlman,B.A. (1989) The production of chromosomal alterations in human lymphocytes by drugs known to interfere with the activity of DNA topoisomerase II. I. m-AMSA. Carcinogenesis, 10, 123-130.
19. Han,Y.H., Austin,M.J., Pommier,Y. and Povirk,L.F. (1993) Small deletion and insertion mutations induced by the topoisomerase II inhibitor teniposide in CHO cells and comparison with sites of drug-stimulated DNA cleavage in vitro. J. Mol. Biol., 229, 52-66.
20. Kaufmann,S.H. (1998) Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochim. Biophys. Acta, 1400, 195-211.
21. Pommier,Y., Fesen,M.R. and Goldwasser,F. (1996) Topoisomerase II inhibitors: the epipodophyllotoxins, m-AMSA and the ellipticine derivatives. In Chabner,B.A. and Longo,D.L. (eds), Cancer Chemotherapy and Biotherapy: Principles and Practice, 2nd Edn. Lippincott-Raven, Philadelphia, PA, pp. 435-461.
22. Pommier,Y. (1997) DNA topoisomerase II inhibitors. In Teicher,B.A. (ed.), Cancer Therapeutics: Experimental and Clinical Agents. Humana Press, Totowa, NJ, Vol. I, pp. 153-174.
23. Hande,K.R. (1998) Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim. Biophys. Acta, 1400, 173-184.
24. Li,T.K. and Liu,L.F. (2001) Tumor cell death induced by topoisomerase-targeting drugs. Annu. Rev. Pharmacol. Toxicol., 41, 53-77.
25. Walker,J.V. and Nitiss,J.L. (2002) DNA topoisomerase II as a target for cancer chemotherapy. Cancer Invest., 20, 570-589.
26. Kreuzer,K.N. and Cozzarelli,N.R. (1979) Escherichia coli mutants thermosensitive for deoxyribonucleic acid gyrase subunit A: effects on deoxyribonucleic acid replication, transcription and bacteriophage growth. J. Bacteriol., 140, 424-435.
27. Felix,C.A. (1998) Secondary leukemias induced by topoisomerase-targeted drugs. Biochim. Biophys. Acta, 1400, 233-255.
28. Rowley,J.D. (1998) The critical role of chromosome translocations in human leukemias. Annu. Rev. Genet., 32, 495-519.
29. Smith,M.A., Rubinstein,L., Anderson,J.R., Arthur,D., Catalano,P.J., Freidlin,B., Heyn,R., Khayat,A., Krailo,M., Land,V.J., Miser,J., Shuster,J. and Vena,D. (1999) Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J. Clin. Oncol., 17, 569-577.
30. Ross,J.A., Potter,J.D., Reaman,G.H., Pendergrass,T.W. and Robison,L.L. (1996) Maternal exposure to potential inhibitors of DNA topoisomerase II and infant leukemia (United States): a report from the Children's Cancer Group. Cancer Causes Control, 7, 581-590.
31. Ross,J.A. (1998) Maternal diet and infant leukemia: a role for DNA topoisomerase II inhibitors? Int. J. Cancer, 11 (suppl.), 26-28.
32. Takagi,E., Kawatsu,H., Shimokata,K., Nishiyama,Y., Kojima,K. and Yoshida,S. (1988) Establishment and characterization of resistant cells to etoposide (VP16) from a mouse breast cancer cell line, FM3A. Jpn. J. Cancer Res., 79, 938-944.
33. Beck,W.T. (1990) Mechanisms of multidrug resistance in human tumor cells. The eoles of P-glycoprotein, DNA topoisomerase II and other factors [Review]. Cancer Treat. Rev., 17, 11-20.
34. Chen,Y.N., Mickley,L.A., Schwartz,A.M., Acton,E.M., Hwang,J.L. and Fojo,A.T. (1990) Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J. Biol. Chem., 265, 10073-10080.
35. Larsen,A.K. and Skladanowski,A. (1998) Cellular resistance to topoisomerase targeted drugs: from drug uptake to cell death. Biochim. Biophys. Acta, 1400, 257-274.
36. Felix,C.A., Walker,A.H., Lange,B.J., Williams,T.M., Winick,N.J., Cheung,N.K., Lovett,B.D., Nowell,P.C., Blair,I.A. and Rebbeck,T.R. (1998) Association of CYP3A4 genotype with treatment-related leukemia. Proc. Natl Acad. Sci. USA, 95, 13176-13181.
37. Elsea,S.H., Osheroff,N. and Nitiss,J.L. (1992) Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast. J. Biol. Chem., 267, 13150-13153.
38. Nitiss,J.L., Liu,Y.X., Harbury,P., Jannatipour,M., Wasserman,R. and Wang,J.C. (1992) Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Res., 52, 4467-4472.
39. Beck,W.T., Danks,M.K., Wolverton,J.S., Kim,R. and Chen,M. (1993) Drug resistance associated with altered DNA topoisomerase II. Adv. Enzyme Regul., 33, 113-127.
40. Feldhoff,P.W., Mirski,S.E., Cole,S.P. and Sullivan,D.M. (1994) Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line. Cancer Res., 54, 756-762.
41. Withoff,S., De Jong,S., De Vries,E.G.E. and Mulder,N.H. (1996) Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance. Anticancer Res., 16, 1867-1880.
42. Dingemans,A.M.C., Pinedo,H.M. and Giaccone,G. (1998) Clinical resistance to topoisomerase-targeted drugs. Biochim. Biophys. Acta, 1400, 275-288.
43. Mirski,S.E., Sparks,K.E., Yu,Q., Lang,A.J., Jain,N., Campling,B.G. and Cole,S.P. (2000) A truncated cytoplasmic topoisomerase II alpha in a drug-resistant lung cancer cell line is encoded by a TOP2A allele with a partial deletion of exon 34. Int. J. Cancer, 85, 534-539.
44. McDaniel,L.S., Rogers,L.H. and Hill,W.E. (1978) Survival of recombination-deficient mutants of Escherichia coli during incubation with nalidixic acid. J. Bacteriol., 134, 1195-1198.
45. Lewin,C.S., Howard,B.M., Ratcliffe,N.T. and Smith,J.T. (1989) 4-Quinolones and the SOS response. J. Med. Microbiol., 29, 139-144.
46. Woodworth,D.L. and Kreuzer,K.N. (1996) Bacteriophage T4 mutants hypersensitive to an antitumor agent that induces topoisomerase-DNA cleavage complexes. Genetics, 143, 1081-1090.
47. Neece,S.H., Carles-Kinch,K., Tomso,D.J. and Kreuzer,K.N. (1996) Role of recombinational repair in sensitivity to an antitumour agent that inhibits bacteriophage T4 type II DNA topoisomerase. Mol. Microbiol., 20, 1145-1154.
48. Lieber,M.R. (1999) The biochemistry and biological significance of nonhomologous DNA end joining: an essential repair process in multicellular eukaryotes. Genes Cells, 4, 77-85.
49. Paques,F. and Haber,J.E. (1999) Multiple pathways of recombination induced by double-strand breaks in Saccharomyces cerevisiae. Microbiol. Mol. Biol. Rev., 63, 349-404.
50. Haber,J.E. (2000) Partners and pathways repainng a double-strand break. Trends Genet., 16, 259-264.
51. Johnson,R.D. and Jasin,M. (2001) Double-strand-break-induced homologous recombination in mammalian cells. Biochem. Soc. Trans, 29, 196-201.
52. Jackson,S.P. (2002) Sensing and repairing DNA double-strand breaks. Carcinogenesis, 23, 687-696.
53. Pedersen-Bjergaard,J. and Rowley,J.D. (1994) The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood, 83, 2780-2786.
54. Lovett,B.D., Lo Nigro,L., Rappaport,E.F., Blair,I.A., Osheroff,N., Zheng,N., Megonigal,M.D., Williams,W.R., Nowell,P.C. and Felix,C.A. (2001) Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation. Proc. Natl Acad. Sci. USA, 98, 9802-9807.
55. Sargent,R.G., Brenneman,M.A. and Wilson,J.H. (1997) Repair of site-specific double-strand breaks in a mammalian chromosome by homologous and illegitimate recombination. Mol. Cell. Biol., 17, 267-277.
56. Liang,F., Han,M., Romanienko,P.J. and Jasin,M. (1998) Homology-directed repair is a major double-strand break repair pathway in mammalian cells. Proc. Natl Acad. Sci. USA, 95, 5172-5177.
57. Takata,M., Sasaki,M.S., Sonoda,E., Morrison,C., Hashimoto,M., Utsumi,H., Yamaguchi-Iwai,Y., Shinohara,A. and Takeda,S. (1998) Homologous recombination and non-homologous end-joining pathways of DNA doublestrand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J., 17, 5497-5508.
58. Thacker,J. (1999) The role of homologous recombination processes in the repair of severe forms of DNA damage in mammalian cells. Biochimie, 81, 77-85.
59. Thompson,L.H. and Schild,D. (1999) The contribution of homologous recombination in preserving genome integrity in mammalian cells. Biochimie, 81, 87-105.
60. Haber,J.E. (2000) Recombination: a frank view of exchanges and vice versa. Curr. Opin. Cell Biol., 12, 286-292.
61. Richardson,C. and Jasin,M. (2000) Frequent chromosomal translocations induced by DNA double-strand breaks. Nature, 405, 697-700.
62. Morrison,C. and Takeda,S. (2000) Genetic analysis of homologous DNA recombination in vertebrate somatic cells. Int. J. Biochem. Cell Biol., 32, 817-831.
63. Aguilera,A., Chavez,S. and Malagon,F. (2000) Mitotic recombination in yeast: elements controlling its incidence. Yeast, 16, 731-754.
64. Sambrook,J., Fritsch,E.F. and Maniatis,T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
65. Rothstein,R. (1991) Targeting, disruption, replacement and allele rescue: integrative DNA transformation in yeast. In Guthrie,C. and Fink,G.R. (eds), Guide to Yeast Genetics and Molecular Biology. Academic Press, San Diego, CA, Vol. 194, pp. 281-301.
66. Yamagata,K., Kato,J., Shimamoto,A., Goto,M., Furuichi,Y. and Ikeda,H. (1998) Bloom's and Werner's syndrome genes suppress hyperrecombination in yeast sgs1 mutant: implication for genomic instability in human diseases. Proc. Natl Acad. Sci. USA, 95, 8733-8738.
67. Tsukamoto,Y., Kato,J. and Ikeda,H. (1996) Hdf1, a yeast Ku-protein homologue, is involved in illegitimate recombination, but not in homologous recombination. Nucleic Acids Res., 24, 2067-2072.
68. Tsukamoto,Y., Kato,J. and Ikeda,H. (1996) Effects of mutations of RAD50, RAD51, RAD52 and related genes on illegitimate recombination in Saccharomyces cerevisiae. Genetics, 142, 383-391.
69. Burns,C.G., Ohi,R., Mehta,S., O'Toole,E.T., Winey,M., Clark,T.A., Sugnet,C.W., Ares,M.,Jr and Gould,K.L. (2002) Removal of a single alpha-tubulin gene intron suppresses cell cycle arrest phenotypes of splicing factor mutations in Saccharomyces cerevisiae. Mol. Cell. Biol., 22, 801-815.
70. Hopfner,K.P., Putnam,C.D. and Tainer,J.A. (2002) DNA double-strand break repair from head to tail. Curr. Opin. Struct. Biol., 12, 115-122.
71. Moore,J.K. and Haber,J.E. (1996) Cell cycle and genetic requirements of two pathways of nonhomologous end-joining repair of double-strand breaks in Saccharomyces cerevisiae. Mol. Cell. Biol., 16, 2164-2173.
72. Lewis,L.K. and Resnick,M.A. (2000) Tying up loose ends: nonhomologous end-joining in Saccharomyces cerevisiae. Mutat. Res., 451, 71-89.
73. Pierce,A.J., Stark,J.M., Araujo,F.D., Moynahan,M.E., Berwick,M. and Jasin,M. (2001) Double-strand breaks and tumorigenesis. Trends Cell Biol., 11, S52-S59.
74. Osheroff,N. (1989) Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. Biochemistry, 28, 6157-6160.
75. Nitiss,J.L., Liu,Y.X. and Hsiung,Y. (1993) A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors. Cancer Res., 53, 89-93.
76. Hsiung,Y., Elsea,S.H., Osheroff,N. and Nitiss,J.L. (1995) A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors. J. Biol. Chem., 270, 20359-20364.
77. Wolfson,J.S. and Hooper,D.C. (1989) Bacterial resistance to quinolones: mechanisms and clinical importance. Rev. Infect. Dis., 11, S960-968.
78. Reece,R.J. and Maxwell,A. (1991) DNA gyrase: structure and function. Crit. Rev. Biochem. Mol. Biol., 26, 335-375.
79. Hooper,D.C. (1998) Bacterial topoisomerases, anti-topoisomerases and anti-topoisomerase resistance. Clin. Infect. Dis., 27, S54-S63.
80. Hooper,D.C. (1993) Quinolone mode of action - new aspects. Drugs, 3, 8-14.
81. Willmott,C.J. and Maxwell,A. (1993) A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex. Antimicrob. Agents Chemother., 37, 126-127.
82. Strumberg,D., Nitiss,J.L., Dong,J., Kohn,K.W. and Pommier,Y. (1999) Molecular analysis of yeast and human type II topoisomerases. Enzyme-DNA and drug interactions. J. Biol. Chem., 274, 28246-28255.
83. Reid,R.J., Fiorani,P., Sugawara,M. and Bjornsti,M.A. (1999) CDC45 and DPB11 are required for processive DNA replication and resistance to DNA topoisomerase I-mediated DNA damage. Proc. Natl Acad. Sci. USA, 96, 11440-11445.
84. Pouliot,J.J., Yao,K.C., Robertson,C.A. and Nash,H.A. (1999) Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes. Science, 286, 552-555.
85. Reagan,M.S., Pittenger,C., Siede,W. and Friedberg,E.C. (1995) Characterization of a mutant strain of Saccharomyces cerevisiae with a deletion of the RAD27 gene, a structural homolog of the RAD2 nucleotide excision repair gene. J. Bacteriol., 177, 364-371.
86. Sommers,C.H., Miller,E.J., Dujon,B., Prakash,S. and Prakash,L. (1995) Conditional lethality of null mutations in RTH1 that encodes the yeast counterpart of a mammalian 5′- to 3′-exonuclease required for lagging strand DNA synthesis in reconstituted systems. J. Biol. Chem., 270, 4193-4196.
87. Wu,X. and Wang,Z. (1999) Relationships between yeast Rad27 and Apn1 in response to apurinic/apyrimidinic (AP) sites in DNA. Nucleic Acids Res., 27, 956-962.
88. Wu,X., Wilson,T.E. and Lieber,M.R. (1999) A role for FEN-1 in nonhomologous DNA end joining: the order of strand annealing and nucleolytic processing events. Proc. Natl Acad. Sci. USA, 96, 1303-1308.
89. Byl,J.A., Cline,S.D., Utsugi,T., Kobunai,T., Yamada,Y. and Osheroff,N. (2001) DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action. Biochemistry, 40, 712-718.
90. You,J.C. (2000) The effects of RAD52 epistasis group genes on various types of spontaneous mitotic recombination in Saccharomyces cerevisiae. Biochem. Biophys. Res. Commun., 270, 112-118.
91. Rowley,J.D. (1994) 1993 Robert R. de Villiers Lecture. Chromosome translocations: dangerous liaisons. Leukemia, 8, S1-S6.
92. Drewinko,B. and Barlogie,B. (1976) Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213. Cancer Treat. Rep., 60, 1295-1306.
93. Kalwinsky,D.K., Look,A.T., Ducore,J. and Fridland,A. (1983) Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis and DNA strand size in cultures of human leukemic lymphoblasts. Cancer Res., 43, 1592-1597.
94. Kaufmann,W.K. and Kies,P.E. (1998) DNA signals for G2 checkpoint response in diploid human fibroblasts. Mutat. Res., 400, 153-167.
95. Elli,R., Chessa,L., Antonelli,A., Petrinelli,P., Ambra,R. and Marcucci,L. (1996) Effects of topoisomerase II inhibition in lymphoblasts from patients with progeroid and "chromosome instability" syndromes. Cancer Genet. Cytogenet., 87, 112-116.
96. Pichierri,P., Franchitto,A., Mosesso,P., Proietti de Santis,L., Balajee,A.S. and Palitti,F. (2000) Werner's syndrome lymphoblastoid cells are hypersensitive to topoisomerase II inhibitors in the G2 phase of the cell cycle. Mutat. Res., 459, 123-133.
97. Raderschall,E., Golub,E.I. and Haaf,T. (1999) Nuclear foci of mammalian recombination proteins are located at single-stranded DNA regions formed after DNA damage. Proc. Natl Acad. Sci. USA, 96, 1921-1926.
98. Alani,E., Subbiah,S. and Kleckner,N. (1989) The yeast RAD50 gene encodes a predicted 153-kD protein containing a purine nucleotide-binding domain and two large heptad-repeat regions. Genetics, 122, 47-57.
99. Longtine,M.S., McKenzie,A.,III, Demarini,D.J., Shah,N.G., Wach,A., Brachat,A., Philippsen,P. and Pringle,J.R. (1998) Additional modules for versatile and economical PCR-based gene deletion and modification in Saccharomyces cerevisiae. Yeast, 14, 953-961.
100. Feldmann,H. and Winnacker,E.L. (1993) A putative homologue of the human autoantigen Ku from Saccharomyces cerevisiae. J. Biol. Chem., 268, 12895-12900.